Market watch: Upcoming market catalysts in Q2 2017

Nature Reviews Drug Discovery 16, 231 (2017). doi:10.1038/nrd.2017.47 Author: Eric Ho Important market catalysts expected in the second quarter of 2017 include regulatory decisions by the FDA on cerliponase alfa (developed by BioMarin) for treatment of CLN2 disease and brigatinib (developed by Takeda) for the treatment of non-small-cell lung cancer (NSCLC), as well as top-line phase

http://feeds.nature.com/~r/nrd/rss/current/~3/wDZ_8hw4B-0/nrd.2017.47

Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Eric Ho Tags: News and Analysis Source Type: research

More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer